Clinical trial
Efficacy and Safety Study of Ursodeoxycholic Acid to Treat Chronic Hepatitis C
NCT00200343 · Tanabe Pharma Corporation, Industry · Completed
Key facts
| NCT number | NCT00200343 |
|---|---|
| Title | Efficacy and Safety Study of Ursodeoxycholic Acid to Treat Chronic Hepatitis C |
| Official title | A 24-week Multicenter Double-blind Control Trial With Ursodeoxycholic Acid in Patients With Chronic Hepatitis C |
| Lead sponsor | Tanabe Pharma Corporation, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Chronic Hepatitis C |
| Intervention type | Drug |
| Interventions | Ursodeoxycholic acid 150mg / day, Ursodeoxycholic acid 600mg / day, Ursodeoxycholic acid 900mg / day |
| Enrollment | 596 |
| Start date | Jul 1, 2002 |
| Completion | Dec 1, 2004 |
| First posted | Sep 20, 2005 |
| Last update posted | Jan 7, 2026 |
| Countries | Japan |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: